• Abhay Raizaday JSS University
  • Praveen Sivadasu JSS UNIVERSITY
  • Swati Uniyal JSS UNIVERSITY
  • S. Hemanth Kumar JSS UNIVERSITY


Cancer nanotechnology


In 21st century scientist all around are trying to formulate the new drug delivery with better efficacy and effectiveness to treat cancer. So their focus has been shifted toward the Nano based drug delivery system because nanotechnology plays with the dimension of the matter typically on the 0.2-to 100-nm scale (Nano scale). When the matter is size reduced its properties changes this is because at the Nano scale the percentage of atoms at the surface of a material becomes more significant. The interesting part of nanotechnology is that when the matter is in bulk possess relatively constant physical properties regardless of their size, but at the Nano scale the matter behave in the different ways. This is because when the material becomes smaller the percentage of atoms at the surface increases relative to the total number of atoms of the material bulk. This can lead to unexpected properties of nanoparticles which are partly due to the surface of the material dominating over the bulk properties. Hence nanotechnology is playing a important role in developing better and effective drug delivery system to fight against cancer.



Download data is not yet available.


Nanoscale Science, Engineering and Technology Subcommittee, Committee on Technology, National Science and Technology Council. The National Nanotechnology Initiative Strategic Plan. National Nanotechnology Initiative; 2004; Available from: http: //nano. gov/html/res/pubs. html.

Nie S, Xing Y, Kim GJ, Simons JW. Nanotechnology applications in cancer. Annu Rev Biomed Eng 2007;9:257–88.

Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles: theory and practice. Pharmacol Rev 2001;53(2):283–318.

Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Sci 2004;303(5665):1818–22.

Brigger I, Dubernet C, Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev 2002;54(5):631–51.

Gaur U, Sahoo SK, De TK, Ghosh PC, Maitra A, Ghosh PK. Biodistribution of fluoresceinated dextran using novel nanoparticles evading reticuloendothelial system. Int J Pharm 2000;202(1–2):1–10.

Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, et al. Phase III Trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005;23(31):7794–803.

Barbara Haley MD, Eugene Frenkel MD. Nanoparticles for drug delivery in cancer treatment. Registry of clinical trials. Clinical Trials gov; Available from: http: //clinicaltrials. gov/ct2/results?term=cancer+nanoparticle.

Jones A, Harris AL. New developments in angiogenesis: A major mechanism for tumor growth and target for therapy. Cancer J Sci Am 1998;4:209 –17.

Baban DF, Seymour LW. Control of tumor vascular permeability. Adv Drug Deliv Rev 1998;34:109 –19.

Hobbs SK, Monsky WL, Yuan F. Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment. Proc Natl Acad Sci USA 1998;95:4607–12.

Rubin P, Casarett G. Microcirculation of tumors. I. Anatomy, function, and necrosis. Clin Radiol 1966;17:220 –9.

Shubik P. Vascularization of tumors: A review. J Cancer Res Clin Oncol 1982;103:211–26.

Jain RK. Delivery of molecular and cellular medicine to solid tumors. Adv Drug Deliv Rev 2001;46:149–68.

Jang SH, Wientjes MG, Lu D. Drug delivery and transport to solid tumors. Pharm Res 2003;20:1337–50.

Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: The key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul 2001;41:189–207.

Maeda H, Wu J, Sawa T. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000;65:271–84.

Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006;5:219–34.

Assaraf YG. Molecular basis of antifolate resistance. Cancer Metast Rev 2007;26:153–81.

Broxterman HJ, Gotink KJ, Verheul HM. Understanding the causes of multidrug resistance in cancer: a comparison of doxorubicin and sunitinib. Drug Resist Update 2009;12:114–26.

Qiao L, Wong BC. Targeting apoptosis as an approach for gastrointestinalcancer therapy. Drug Resist Updates 2009;12:55–64.

Chen AM, Zhang M, Wei DG, Stueber D, Taratula O, Minko T, et al. Co-delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells. Small 2009;5:2673–7.

Hotchkiss RS, Strasser A, McDunn JE, Swanson PE. Cell death. N Engl J Med 2009;361:1570–83.

Paoluzzi L, O’Connor OA. Targeting survival pathways in lymphoma. Adv Exp Med Biol 2010;687;79–96.

Schleicher SM, Moretti L, Varki V, Lu B. Progress in the unraveling of theendoplasmic reticulum stress/autophagy pathway and cancer: implications for future therapeutic approaches. Drug Resist Updates 2010;13:79–86.

Grivennikov SI, Greten FR, Karin M. Immunity, inflammation and cancer. Cell 2010;140:883–99.

Gyrd-Hansen M, Meier P. IAPs: from caspase inhibitors to modulators of NF-kB, inflammation and cancer. Nat Rev Cancer 2010;10:561–74.

Alina S, Yoav DL, Henk JB, Yehuda G. Assarafd. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance, Drug Resist Updates 2011;14:150–63.

Basu S, Chaudhuri P, Sengupta S. Targeting oncogenic signaling pathways by exploiting nanotechnology. Cell Cycle 2009;8:3480–7.

Parker N, Turk MJ, Westrick E, Lewis JD, Low PS, Leamon CP. Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem 2005;338:284–93.

Low PS, Henne WA, Doorneweerd DD. Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases. Acc Chem Res 2008;41:120–9.

Xia W, Low PS. Folate-targeted therapies for cancer. J Med Chem 2010;53:6811–24.

Wang Z, Li Y, Ahmad A, Azmi AS, Kong D, Banerjee S, et al. Targeting miRNAs involved in cancer stem cell and EMT regulation: an emerging concept in overcoming drug resistance. Drug Resist Updates 2010;13:109–18.

Wang JQ, Tao XY, Zhang YF, Wei DZ, Ren YH. Reversion of multidrugresistance by tumor targeted delivery of antisense oligodeoxynucleotides in hydroxypropyl-chitosan nanoparticles. Biomaterials 2010;31:4426–33.

Liu F, Park JY, Zhang Y, Conwell C, Liu Y, Bathula SR, et al. Targeted cancer therapy with novel high drug-loading nanocrystals. J Pharm Sci 2010;99:3542–51.

Ganta S, Amiji M. Coadministration of paclitaxel and curcumin in nanoemulsionformulations to overcome multidrug resistance in tumor cells. Mol Pharm 2010;6:928–39.

Kuo WS, Ku YC, Sei HT, Cheng FY, Yeh C. Paclitaxel-loaded stabilizerfreepoly(d, l-lactide-co-glycolide) nanoparticles conjugated with quantum dots for reversion of anticancer drug resistance and cancer cellular imaging. J Chin Chem Soc 2009;56:923-34.

Gagnadoux F, Hureaux J, Vecellio L, Urban T, Le Pape A, Valo I, et al. Aerosolized chemotherapy. J Aerosol Med Pulmon Drug Deliv 2008;21:61–9.

Zhu L, Huo ZL, Wang LL, Tong X, Xiao Y, Ni KY. Targeted delivery of methotrexate to skeletal muscular tissue by thermosensitivemagnetoliposomes. Int J Pharmacol 2009;370:136–43.

MacDiarmid JA, Amaro-Mugridge NB, Madrid-Weiss J. Sequential treatment of drug-resistant tumors with targeted minicells containing siRNA or a cytotoxic drug. Nat. Biotechnol 2009;27:643–51.

Chen BA, Dai YY, Wang XM. Synergistic effect of the combination of nanoparticulate Fe3O4 and Au with daunomycin on K562/A02 cells. Int J Nanomed 2008;3:343–50.

Pinhassi RI, Assaraf YG, Farber S, Stark M, Ickowicz D, Drori S, et al. Arabinogalactan-folate-drug conjugate for targeted delivery and target-activated release of anticancer drugs to folatereceptoroverexpressing cells. Biomacromol 2010;11:294–303.

Akita H, Kudo A, Minoura A, Yamaguti M, Khalil IA, Moriguchi R, et al. Multi-layered nanoparticles for penetrating the endosome and nuclear membrane via a step-wise membrane fusion process. Biomaterials 2009;30:2940–9.

Schroder T, Niemeier N, Afonin S, Ulrich AS, Krug HF, Brase S. Peptoidicamino-and guanidinium-carrier systems: targeted drug delivery into the cell cytosol or the nucleus. J Med Chem 2008;51:376–9.

Xu ZP, Niebert M, Porazik K, Walker TL, Cooper HM, Middelberg AP, et al. Subcellular compartment targeting of layered double hydroxide nanoparticles. J Control Release 2008;130:86–94.

Chien AJ, Illi JA, Ko AH, Korn WM, Fong L, Chen LM, et al. A Phase I study of a 2-day lapatinibchemosensitization pulse preceding nanoparticle albumin-bound paclitaxel for advanced solid malignancies. Clin Cancer Res 2009;15:5569–75.

Conlin AK, Seidman AD, Bach A. Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer. Clin Breast Cancer 2010;10:281–7.

Robidoux A, Buzdar AU, Quinaux E, Jacobs S, Rastogi P. A phase II neoadjuvant trial of sequential nanoparticle albumin-bound paclitaxel followed by 5-fluorouracil/ epirubicin/ cyclophosphamide in locally advanced breast cancer. Clin Breast Cancer 2010;10:81–6.

Roy V, La Plant BR, Gross GG, Bane CL, Palmieri FM. Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane (R)) in combination with gemcitabine in patients with metastatic breast cancer (N0531). Ann Oncol 2009;20:449–53.

Stinchcombe TE, Socinski MA, Lee CB, Hayes DN, Moore DT, Goldberg RM, et al. Phase I trial of nanoparticle albumin-bound paclitaxel in combination with gemcitabine in patients with thoracic malignancies. J Thorac Oncol 2008;3:521–6.

Teneriello MG, Tseng PC, Crozier M. Phase II evaluation of nanoparticle albumin-bound paclitaxel in platinum-sensitive patients with recurrent ovarian, peritoneal, or fallopian tube cancer. J Clin Oncol 2009;27:1426–31.

Zhou QH, Sun X, Zeng LY, Liu J, Zhang ZR. A randomized multicenter phase II clinical trial of mitoxantrone-loaded nanoparticles in the treatment of 108 patients with unresected hepatocellular carcinoma. Nanomed Nanotechnol Biol Med 2009;5:419–23.

Davis ME, Zuckerman JE, Choi CH. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010;464:1067–70.

Liu Z, Chen K, Davis C, Sherlock S, Cao QZ, Chen XY, et al. Drug delivery with carbon nanotubes for in vivo cancer treatment. Cancer Res 2008;68:6652–60.

Khdair A, Chen D, Patil Y, Ma LN, Dou QP, Shekhar MP, et al. Nano particle-mediated combination chemotherapy and photodynamic therapy overcomes tumor drug resistance. J Control Release 2010;141:137–44.

Kwon IC. Theragnostic imaging of tumors by polymer nanoparticle. Nanomed Nanotechnol Biol Med 2007;3:342–3.

O’Brien ME, Wigler N, Inbar M. Reduced cardiotoxicity and comparable efficacy in a Phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) vs. conventional doxorubicin for firstline treatment of metastatic breast cancer. Ann Oncol 2004;15:440–9.

Working PK, Newman MS, Sullivan T. Reduction of the cardiotoxicity of doxorubicin in rabbits and dogs by encapsulation in long-circulating, pegylated liposomes. J Pharmacol Exp Ther 1999;289:1128 –33.

Lasic DD. Doxorubicin in sterically stabilized liposomes. Nature 1996;380:561–2.

Lasic D, Martin F. Stealth Liposomes. Boca Raton (FL): CRC Press; 1995. p. 22–41.

Gordon AN, Fleagle JT, Guthrie D. Recurrent epithelial ovarian carcinoma: A randomized Phase III study of pegylated liposomal doxorubicin vs topotecan. J Clin Oncol 2001;19:3312–22.

Northfelt DW, Dezube BJ, Thommes JA. Pegylated-liposomal doxorubicin vs. doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi’s sarcoma: Results of a randomized Phase III clinical trial. J Clin Oncol 1998;16:2445–51.

Stewart S, Jablonowski H, Goebel FD. Randomized comparative trial of pegylated liposomal doxorubicin vs. bleomycin and vincristine in the treatment of AIDS-related Kaposi’s sarcoma. International pegylated liposomal doxorubicin study group. J Clin Oncol 1998;16:683–91.

Hofheinz RD, Gnad-Vogt SU, Beyer U. Liposomal encapsulated anti-cancer drugs. Anticancer Drugs 2005;16:691–707.

Gill PS, Wernz J, Scadden DT. Randomized Phase III trial of liposomal daunorubicin vs. doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi’s sarcoma. J Clin Oncol 1996;14:2353–64.

Desai N, Trieu V, Yao R. Increased endothelial transcytosis of nanoparticle albumin-bound paclitaxel (AB1-007) by endothelial gp60 receptors: A pathway inhibited by Taxol. San Antonio Breast Cancer Symposium; 2004. p. 1071.

Paal K, Muller J, Hegedus L. High affinity binding of paclitaxel to human serum albumin. Eur J Biochem 2001;268:2187–91.

Purcell M, Neault JF, Tajmir-Riahi HA. Interaction of taxol with human serum albumin. Biochim Biophys Acta 2000;1478:61–8.

Che Y, Luo A, Wang H. The differential expression of SPARC in esophageal squamous cell carcinoma. Int J Mol Med 2006;17:1027–33.

Koukourakis MI, Giatromanolaki A, Brekken RA. Enhanced expression of SPARC/osteonectin in the tumor-associated stroma of non-small cell lung cancer is correlated with markers of hypoxia/ acidity and with poor prognosis of patients. Cancer Res 2003;63:5376–80.

Desai N, Trieu V, Yao Z. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res 2006;12:1317–24.

Abraxane prescribing information. Schaumberg (IL): Abraxis Oncology; 2005.

Gradishar WJ, Tjulandin S, Davidson N. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005;23:7794–803.

O’Shaughnessy J, Blum J, Sandbach J. Weekly nanoparticle albumin paclitaxel (Abraxane) results in long term disease control in patients with taxane-refractory metastatic breast cancer. San Antonio Breast Cancer Symposium; 2000.

Petrylak DP, Tangen CM, Hussain MH. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513–20.

Tannock IF, de Wit R, Berry WR. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502–12.

Farokhzad OC, Cheng J, Teply BA. Targeted nanoparticle aptamerbioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci USA 2006;103:6315–20.

Sahoo SK, Ma W, Labhasetwar V. Efficacy of transferrin-conjugated paclitaxel-loaded nanoparticles in a murine model of prostate cancer. Int J Cancer 2004;112:335–40.

Hattori Y, Maitani Y. Folate-linked lipid-based nanoparticle for targeted gene delivery. Curr Drug Deliv 2005;2:243–52.



How to Cite

Hemant, K., A. Raizaday, P. Sivadasu, S. Uniyal, and S. H. Kumar. “CANCER NANOTECHNOLOGY: NANOPARTICULATE DRUG DELIVERY FOR THE TREATEMENT OF CANCER”. International Journal of Pharmacy and Pharmaceutical Sciences, vol. 7, no. 3, Mar. 2015, pp. 40-46,



Review Article(s)